查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
精神分裂症药物市场与 COVID-19 影响分析，按治疗类别、治疗、分销渠道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1339907

精神分裂症药物市场与 COVID-19 影响分析，按治疗类别、治疗、分销渠道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Schizophrenia Drugs Market with COVID-19 Impact Analysis, by Therapeutic Class, by Treatment, by Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年精神分裂症药物市场规模为75.7921亿美元，2023年至2030年復合年增长率为5.81%。

精神分裂症药物市场-市场动态：

  • 精神分裂症及相关疾病的患病率不断增加。
  • 精神分裂症和相关疾病发病率的增加，以及更容易患迟发性精神分裂症的人口老龄化，是整个预测期内推动市场扩张的主要驱动力。据世界卫生组织称，到2022年，精神分裂症将影响全球2400万人。此外，随着人口普遍老龄化，这一数字预计将进一步上升。精神分裂症患病率的增加推动了对有效治疗的需求，从而推动了精神分裂症药物市场的发展。随着越来越多的人被诊断出来，对控制症状的药物治疗的需求也越来越大，这推动了该领域的研究、创新和市场开发。

精神分裂症药物市场 - 主要见解：

  • 根据我们的研究分析师分享的分析，全球精神分裂症药物市场预计在预测期内（2023-2030）每年将以 5.81% 左右的复合年增长率增长
  • 由于精神分裂症及相关疾病的患病率不断增加，精神分裂症药物行业预计将以显着的速度增长
  • 根据治疗类别细分，预计第二代将在 2022 年显示出最大的市场份额
  • 根据治疗细分，注射剂是 2022 年的主导类型
  • 从分布细分来看，医院药房是2022年的主导类型
  • 按地区划分，北美是 2022 年的主要收入来源

精神分裂症药物市场-細項分析：

全球精神分裂症药物市场根据治疗类别、治疗、分销渠道和地区进行细分。

市场根据治疗类别分为几类：第二代、第三代和其他。由于精神分裂症等精神健康疾病的发生频率增加等因素，第二代抗精神病药物预计将在预测期内增长，特别是在治疗精神分裂症患者的妄想和幻觉等症状方面特别有效。

市场根据治疗分为两类：口服和注射。注射剂市场占据主导地位。注射型精神分裂症药物，特别是长效注射剂 (LAI)，是最复杂的治疗方法之一。长效注射剂通常有助于消除与口服精神分裂症治疗相关的缺点。注射剂的一些优点包括提高对治疗方案的依从性、减少復发以及避免患者出现不可逆的认知和神经损伤。

精神分裂症药物市场-地理洞察：

从地域上看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太地区以及中东和非洲地区。这些区域根据开展业务的国家进一步划分。由于普通人群中精神分裂症和相关精神障碍的发病率不断上升、医疗保健基础设施健全、老年人口不断增加、医疗保健支出高以及主要市场参与者的存在，预计北美将占据重要的市场份额。根据国家精神疾病联盟 (NAMI) 自 2022 年 6 月起的更新数据，精神分裂症每年影响美国约 150 万成年人。因此，预计该地区对精神分裂症药物的需求将会增加。将推动正在研究的北美市场的增长。

精神分裂症药物市场-竞争格局：

公司通过多种渠道销售产品，包括企业网站、电子商务网站、零售商、分销商和最终消费者。产品製造商在多个方面进行竞争，包括产品成本、性能、产品製造、技术、声誉和可用性。企业用来扩大影响力和扩大市场份额的一些主要技术包括新产品发布、分销网络开发、研发支出以及併购。例如，在 2022 年，为了研究、开发和销售用于潜在治疗神经精神疾病的新型多巴胺受体调节剂，艾伯维 (AbbVie) 和 Gedeon Richter 签署了一项新的共同开发和许可协议。

最近的发展：

2023年5月，治疗精神分裂症的全新药物UZEDY获得FDA批准。 UZEDY 是梯瓦製药工业有限公司生产的一种药物，采用共聚物技术在一到两个月的时间内逐渐释放活性成分利培酮。

该研究的主要特点：

  • 这项关于精神分裂症药物市场的拟议研究提供了市场规模（百万美元）、年复合成长率（CAGR%）和预测估计（2023-2030），以 2022 年为基准年
  • 该报告为客户提供有关精神分裂症药物市场的最新趋势见解。
  • 该研究报告阐明了不同细分市场/国家的潜在增长机会，并解释了精神分裂症药物市场有吸引力的投资主张矩阵
  • 总体报告确定了新的投资机会、老牌参与者面临的挑战以及精神分裂症药物市场维持的增长因素
  • COVID-19 对精神分裂症药物市场规模、预测、复合年增长率和市场动态的影响将在研究范围下详细讨论。还将详细介绍新冠疫情后精神分裂症药物市场的情况。
  • 为了让本报告的用户全面了解精神分裂症药物市场，我们还包括了精神分裂症药物市场的竞争格局和关键创新者分析。
  • 该研究包括增长前景映射分析，其中所有行业细分都根据其市场规模、增长率和吸引力进行基准测试。
  • 该报告提供了主要市场参与者的详细公司概况，这将帮助用户了解在精神分裂症药物市场运营的参与者的财务信息和战略倡议。
  • 此外，报告还揭示了全球和区域市场主要参与者的重要收购和兼併、合作和合资、新产品推出、研发、区域扩张。
  • 全球精神分裂症药物市场报告主要面向该行业的各个利益相关者，包括供应商、投资者、新进入者、分销商和财务分析师

目录

第一章：精神分裂症药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按治疗类别分類的精神分裂症药物市场片段
    • 精神分裂症药物市场摘要（按治疗）
    • 按分销渠道分類的精神分裂症药物市场片段
    • 按国家/地区分類的精神分裂症药物市场摘要
    • 按地区分類的精神分裂症药物市场片段
  • 竞争洞察

第 3 章：精神分裂症药物主要市场趋势

  • 精神分裂症药物市场驱动因素
    • 市场驱动因素的影响分析
  • 精神分裂症药物市场限制
    • 市场限制影响分析
  • 精神分裂症药物市场机会
  • 精神分裂症药物市场未来趋势

第 4 章：精神分裂症药物行业研究

  • PEST分析
  • 波特五力分析
  • 增长前景图
  • 规范架构分析

第 5 章：精神分裂症药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的细分市场
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：精神分裂症药物市场格局

  • 2022 年精神分裂症药物市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：精神分裂症药物市场 - 按治疗类别

  • 概述
    • 按治疗类别分類的细分市场份额分析
    • 第二代
    • 第三代
    • 其他

第 8 章：精神分裂症药物市场 - 按治疗分类

  • 概述
    • 按处理方式分類的细分市场份额分析
    • 口服
    • 可注射

第 9 章：精神分裂症药物市场 - 按分销渠道

  • 概述
    • 按分销渠道分類的细分市场份额分析
    • 医院药房
    • 零售药店
    • 网上药店

第 10 章：精神分裂症药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场份额分析
  • 北美
    • 概述
    • 北美精神分裂症药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗类别）
    • 北美市场规模和预测（按不同处理方式）
    • 北美市场规模和预测（按分销渠道）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲精神分裂症药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按治疗类别）
    • 欧洲市场规模和预测（按处理方式）
    • 欧洲市场规模和预测（按分销渠道）
    • 德国
    • 意大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区精神分裂症药物主要製造商
    • 亚太地区市场规模和预测（按国家）
    • 亚太地区市场规模和预测（按治疗类别）
    • 亚太地区市场规模和预测（按不同处理方式）
    • 亚太地区市场规模和预测（按分销渠道）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳大利亚
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉美
    • 概述
    • 拉丁美洲精神分裂症药物主要製造商
    • 拉丁美洲市场规模和预测（按国家）
    • 拉丁美洲市场规模和预测（按治疗类别）
    • 拉丁美洲市场规模和预测（按不同处理方式）
    • 拉丁美洲市场规模和预测（按分销渠道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲精神分裂症药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按治疗类别）
    • 中东和非洲市场规模及预测（按不同处理方式）
    • 中东和非洲市场规模及预测（按分销渠道）
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 火鸡
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 精神分裂症药物行业

  • 竞争仪表板
  • 公司简介
    • Vanda Pharmaceuticals
    • Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
    • Sumitomo Dainippon Pharma
    • Recordati Rare Diseases
    • Pfizer
    • Otsuka Pharmaceutical
    • Novartis
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Intra-Cellular Therapies
    • H. Lundbeck A/S
    • Eli Lilly and Company
    • Bristol Myers Squibb
    • AstraZeneca
    • Allergan (now part of AbbVie)
    • Alkermes plc

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联繫我们
Product Code: ANV1631

REPORT HIGHLIGHT

Schizophrenia Drugs Market size was valued at USD 7,579.21 Million in 2022, expanding at a CAGR of 5.81% from 2023 to 2030.

Schizophrenia drugs are pharmacological chemicals that are used to treat the symptoms of schizophrenia, a complicated mental condition marked by disordered thoughts, feelings, and perceptions. These medications primarily target neurotransmitter imbalances in the brain, specifically dopamine and serotonin, in order to reduce hallucinations, delusions, disordered thinking, and social disengagement. Schizophrenia medications attempt to improve the quality of life for those suffering from the condition by reducing symptoms and increasing functional recovery, frequently as part of a complete treatment plan that includes counseling and psychological support.

Schizophrenia Drugs Market- Market Dynamics:

  • Increasing prevalence of schizophrenia and associated disorders.
  • The increased frequency of schizophrenia and related illnesses, along with an aging population that is more vulnerable to late-onset schizophrenia, is the primary driver driving market expansion throughout the projection period. According to the WHO, schizophrenia will affect 24 million people globally by 2022. Furthermore, with the aging of people in general, the figure is anticipated to rise further. The increased prevalence of schizophrenia is driving the need for effective treatment, moving the schizophrenia medications market forward. As more people are diagnosed, there is a larger demand for pharmacological treatments to control symptoms, which is fueling research, innovation, and market development in this sector.

Schizophrenia Drugs Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Schizophrenia Drugs market is estimated to grow annually at a CAGR of around 5.81% over the forecast period (2023-2030)
  • The Schizophrenia Drugs industry is projected to grow at a significant rate due to the increasing prevalence of schizophrenia and associated disorders
  • Based on therapeutic class segmentation, second generation was predicted to show maximum market share in the year 2022
  • Based on treatment segmentation, injectable was the leading type in 2022
  • Based on distribution segmentation, hospital pharmacies was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Schizophrenia Drugs Market- Segmentation Analysis:

The Global Schizophrenia Drugs Market is segmented on the basis of Therapeutic Class, Treatment, Distribution Channel, and Region.

The market is divided into categories based on therapeutic class: Second Generation, Third Generation, and Other. The Second-generation antipsychotics segment is expected to grow over the forecast period, owing to the factors such as the increased frequency of mental health illnesses such as schizophrenia, particularly effective in treating symptoms such as delusions and hallucinations in people with schizophrenia.

The market is divided into categories based on treatment: oral and injectable. The injectable segment dominates the market. Injectable-based schizophrenia medicines, particularly long acting injectables (LAIs), are among the most sophisticated kinds of therapy. Long-acting injectables frequently aid in the elimination of the drawbacks associated with oral schizophrenia therapy. Some of the advantages of the injectable include improved adherence to treatment regimens, reduced relapses, and the avoidance of irreversible cognitive and neurological impairment in patients.

Schizophrenia Drugs Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold a significant market share the market owing to the growing incidence of schizophrenia and associated mental disorders in the general population, the presence of robust healthcare infrastructure rising geriatric population, high spending on healthcare, and the presence of major market players. Schizophrenia affects about 1.5 million adults annually in the United States, in accordance to the National Alliance of Mental Illness (NAMI) update from June 2022. As a result, it is anticipated that there will be a demand for schizophrenia drugs in the area, which will drive growth in the North American market under study.

Schizophrenia Drugs Market- Competitive Landscape:

Companies sell their products through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Products makers compete on a variety of aspects, including product costs, performance, product making, technology, reputation, and availability. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new product launches, distribution network development, R&D spending, and mergers and acquisitions. For instance, in 2022, In order to conduct research, develop, and market novel dopamine receptor modulators for the potential treatment of neuropsychiatric illnesses, AbbVie and Gedeon Richter have engaged into a new co-development and license agreement.

Recent Developments:

In May 2023, UZEDY, a brand-new medication for the treatment of schizophrenia, received FDA approval. UZEDY is a medication produced by Teva Pharmaceutical Industries, Ltd. that gradually releases the active component, risperidone, over the course of one to two months using copolymer technology.

Key features of the study:

  • This proposed research study on Schizophrenia Drugs market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Schizophrenia Drugs market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Schizophrenia Drugs market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Schizophrenia Drugs market
  • Impact of COVID-19 on Schizophrenia Drugs market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Schizophrenia Drugs market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Schizophrenia Drugs market, we have also included competitive landscape and key innovator analysis for the Schizophrenia Drugs market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Schizophrenia Drugs market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Schizophrenia Drugs market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SCHIZOPHRENIA DRUGS MARKET KEY PLAYERS

  • Vanda Pharmaceuticals
  • Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
  • Sumitomo Dainippon Pharma
  • Recordati Rare Diseases
  • Pfizer
  • Otsuka Pharmaceutical
  • Novartis
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Intra-Cellular Therapies
  • H. Lundbeck A/S
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • AstraZeneca
  • Allergan (now part of AbbVie)
  • Alkermes plc

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY THERAPEUTIC CLASS

  • Second Generation
  • Third Generation
  • Other

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY TREATMENT

  • Oral
  • Injectable

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL SCHIZOPHRENIA DRUGS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Schizophrenia Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Schizophrenia Drugs Market Snippet by Therapeutic Class
    • 2.1.2. Schizophrenia Drugs Market Snippet by Treatment
    • 2.1.3. Schizophrenia Drugs Market Snippet by Distribution Channel
    • 2.1.4. Schizophrenia Drugs Market Snippet by Country
    • 2.1.5. Schizophrenia Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Schizophrenia Drugs Key Market Trends

  • 3.1. Schizophrenia Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Schizophrenia Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Schizophrenia Drugs Market Opportunities
  • 3.4. Schizophrenia Drugs Market Future Trends

4. Schizophrenia Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Schizophrenia Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Schizophrenia Drugs Market Landscape

  • 6.1. Schizophrenia Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Schizophrenia Drugs Market - By Therapeutic Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutic Class, 2022 & 2030 (%)
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Other

8. Schizophrenia Drugs Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable

9. Schizophrenia Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Schizophrenia Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Schizophrenia Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Schizophrenia Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Schizophrenia Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Schizophrenia Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Schizophrenia Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapeutic Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Schizophrenia Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Vanda Pharmaceuticals
    • 11.2.2. Sunovion Pharmaceuticals (part of Sumitomo Dainippon Pharma)
    • 11.2.3. Sumitomo Dainippon Pharma
    • 11.2.4. Recordati Rare Diseases
    • 11.2.5. Pfizer
    • 11.2.6. Otsuka Pharmaceutical
    • 11.2.7. Novartis
    • 11.2.8. Johnson & Johnson (Janssen Pharmaceuticals)
    • 11.2.9. Intra-Cellular Therapies
    • 11.2.10. H. Lundbeck A/S
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Bristol Myers Squibb
    • 11.2.13. AstraZeneca
    • 11.2.14. Allergan (now part of AbbVie)
    • 11.2.15. Alkermes plc

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Schizophrenia Drugs Market: Therapeutic Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
  • TABLE Global Schizophrenia Drugs Market, by Therapeutic Class 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Schizophrenia Drugs Market, by Treatment 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Schizophrenia Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Schizophrenia Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Schizophrenia Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Therapeutic Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)